Author

G. L. Hirst

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:spatial domain detection· 1

Frequent Co-Authors

C. Yau· 2 shared A. Basu· 1 shared A. D. Borowsky· 1 shared A. Demichele· 1 shared A. Glencer· 1 shared A. Officer· 1 shared D. M. Wolf· 1 shared D. Nachmanson· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Yau

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tumor microenvironmental determinants of high-risk DCIS progression

A. Glencer, K. Ramalingam, N. Schindler, H. Mori, P. Ghule, K. C. Lee, D. Nachmanson, A. Officer, O. Harismendy, J. L. Stein, G. Stein, D. Weaver, C. Yau, G. L. Hirst, M. J. Campbell, , A. D. Borowsky

This study identifies immune microenvironment features and myoepithelial continuity as key determinants of progression in high-risk DCIS.

bioRxiv · Dec 1, 2023 · PreprintCancer Biology

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

K. Yu, A. Basu, C. Yau, D. M. Wolf, H. Goodarzi, S. Bandyopadhyay, J. E. Korkola, G. L. Hirst, S. Asare, I-SPY 2 TRIAL, A. Demichele, N. Hylton, D. Yee, L. Esserman, L. van 't Veer, M. Sirota

This study uses computational drug repositioning to identify agents that can sensitize drug-resistant breast tumors, finding fulvestrant effective across multiple treatment and receptor subtypes.

bioRxiv · Mar 30, 2023Cell Biology